We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+26.28%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$171M
AUM Growth
+$47.3M
Cap. Flow
+$20.1M
Cap. Flow %
11.76%
Top 10 Hldgs %
88.23%
Holding
35
New
6
Increased
3
Reduced
2
Closed
15

Top Buys

Rank Stock Value
1
TRML
Tourmaline Bio
TRML
+$6.39M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$5.37M
3
ROIV icon
Roivant Sciences
ROIV
+$4.87M
4
ADMA icon
ADMA Biologics
ADMA
+$1.48M
5
IMVT icon
Immunovant
IMVT
+$1.01M

Top Sells

Rank Stock Value
1
QIPT
Quipt Home Medical
QIPT
+$5.6M
2
TELA icon
TELA Bio
TELA
+$3.86M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.15M
4
GOSS icon
Gossamer Bio
GOSS
+$2.55M
5
CABA icon
Cabaletta Bio
CABA
+$2.28M

Sector Composition

Rank Sector Weight
1 Healthcare 82.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALIM
1
DELISTED
Alimera Sciences
ALIM
$58.8M 34.31%
13,608,533
– –
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$81.4B
$30.1M 17.57%
+150,000
New +$26.9M
HRTX icon
3
Heron Therapeutics
HRTX
$71.7M
$11.9M 6.93%
6,986,744
– –
ADMA icon
4
ADMA Biologics
ADMA
$2.2B
$9.66M 5.64%
2,136,100
+400,000
+23% +$1.48M
JSPR icon
5
Jasper Therapeutics
JSPR
$26.4M
$8.55M 4.99%
1,121,904
– –
TRML
6
DELISTED
Tourmaline Bio
TRML
$8.35M 4.88%
+319,080
New +$6.39M
PRAX icon
7
Praxis Precision Medicines
PRAX
$10B
$7.7M 4.5%
345,666
-1
-0% -$18
IMGN
8
DELISTED
Immunogen Inc
IMGN
$5.62M 3.28%
189,500
– –
ROIV icon
9
Roivant Sciences
ROIV
$26B
$5.62M 3.28%
+500,000
New +$4.87M
OPTN
10
DELISTED
OptiNose
OPTN
$4.9M 2.86%
253,124
+13,333
+6% +$243K
LNTH icon
11
Lantheus
LNTH
$6.58B
$4.65M 2.71%
75,000
– –
INSP icon
12
Inspire Medical Systems
INSP
$1.76B
$3.66M 2.14%
18,000
+2,700
+18% +$437K
APLS
13
DELISTED
Apellis Pharmaceuticals
APLS
$2.99M 1.75%
50,000
– –
NSPR icon
14
InspireMD
NSPR
$36.1M
$2.54M 1.48%
904,029
– –
ACRS icon
15
Aclaris Therapeutics
ACRS
$841M
$1.85M 1.08%
+1,761,595
New +$5.37M
GERN icon
16
Geron
GERN
$949M
$1.64M 0.96%
778,500
– –
IMVT icon
17
Immunovant
IMVT
$8.17B
$1.16M 0.68%
+27,500
New +$1.01M
NVNO
18
enVVeno Medical
NVNO
$7.09M
$885K 0.52%
+4,921
New +$784K
TELA icon
19
TELA Bio
TELA
$41.6M
$513K 0.3%
77,500
-668,587
-90% -$3.86M
ELEV
20
DELISTED
Elevation Oncology
ELEV
$267K 0.16%
497,299
– –
ANNX icon
21
Annexon
ANNX
$881M
– –
-459,746
Closed -$1.09M
CABA icon
22
Cabaletta Bio
CABA
$450M
– –
-150,000
Closed -$2.28M
CGEM icon
23
Cullinan Oncology
CGEM
$1.16B
– –
-75,000
Closed -$679K
EDSA icon
24
Edesa Biotech
EDSA
$51.3M
– –
-183,088
Closed -$810K
GOSS icon
25
Gossamer Bio
GOSS
$86M
– –
-3,065,136
Closed -$2.55M
1
2

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SA
swisspartners Advisors Zurich, Switzerland $159M AUM 36.51% 1-Year Est. Return
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
CF
CBM Financial Austin, Texas $160M AUM
RP
RIHO Partners Tucson, Arizona $159M AUM

Velan Capital Investment Management's Q4 2023 Portfolio in Review

As of Q4 2023, Velan Capital Investment Management held 35 positions worth $171M, up 38% from $124M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Velan Capital Investment Management deployed $20.1M of net new capital in Q4 2023, opening 6 new positions and adding to 3 existing holdings. Its largest new stake was Tourmaline Bio: 319,080 shares worth $8.35M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was TELA Bio, an estimated $3.86M trimmed.

  • Velan Capital Investment Management's largest Q4 2023 buy was Tourmaline Bio: 319,080 shares worth $8.35M.
  • Velan Capital Investment Management added most to ADMA Biologics in Q4 2023, an estimated $1.48M increase.
  • Velan Capital Investment Management's biggest Q4 2023 reduction was TELA Bio, cutting an estimated $3.86M.
  • Velan Capital Investment Management fully exited Quipt Home Medical in Q4 2023, selling an estimated $5.6M.
  • Velan Capital Investment Management's ten largest holdings make up 88% of its $171M portfolio in Q4 2023.
  • Velan Capital Investment Management opened 6 new positions and closed 15 in Q4 2023.
  • Velan Capital Investment Management's portfolio value rose 38% quarter-over-quarter to $171M.

Based on Velan Capital Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.